Wednesday . August 05, 2026

You are here

Home
Pfizer

Pfizer

Pfizer beats earnings estimates, targets $2.5 billion in additional cost cuts

The company is also counting on newer medicines to lessen its ‌dependence on ‌aging blockbuster drugs
Pfizer has said it expects to return to stronger growth after 2028

By Reuters · 04 August 2026

Belgian court throws out Covid vaccine case against EU chief

By AFP · 21 January 2025

UK regulator approves updated Pfizer-BioNTech COVID vaccine

By Reuters · 05 September 2023

Pfizer in talks to buy Seagen for likely for more than $30 billion - WSJ

By Reuters · 27 February 2023

Pfizer boosts COVID-19 vaccine sales forecast by $2bn

By Reuters · 01 November 2022

FDA asks Pfizer to test second Paxlovid course in patients with COVID-19 rebound

By Reuters · 19 August 2022

Flush with cash, Pfizer buys Global Blood Therapeutics in $5.4bn deal

By Reuters · 08 August 2022

Pfizer profit beats estimates on higher demand for COVID products

By Reuters · 28 July 2022

Special

Pfizer to provide medicines to 1.2bn people in 45 countries on not-for-profit basis

By SHAFQUAT ALI · 07 July 2022

US approves Pfizer and Moderna vaccines for youngest children

By AFP · 17 June 2022

Pfizer seeks US authorization of COVID-19 vaccine for young children

By Reuters · 02 June 2022

Pfizer keeps COVID sales forecast unchanged as pandemic curbs ease: Reuters

By Reuters · 03 May 2022

US to widen COVID antiviral pill distribution

By Reuters · 26 April 2022

Print Edition

Read pdf version Subscribe now

© 2026 SAUDI RESEARCH & PUBLISHING COMPANY, All Rights Reserved And subject to Terms of Use Agreement.